Advertisement

World Journal of Surgery

, Volume 38, Issue 1, pp 68–79 | Cite as

Thyroid Lobectomy for Papillary Thyroid Cancer: Long-term Follow-up Study of 1,088 Cases

  • Kenichi Matsuzu
  • Kiminori Sugino
  • Katsuhiko Masudo
  • Mitsuji Nagahama
  • Wataru Kitagawa
  • Hiroshi Shibuya
  • Keiko Ohkuwa
  • Takashi Uruno
  • Akifumi Suzuki
  • Syunsuke Magoshi
  • Junko Akaishi
  • Chie Masaki
  • Michikazu Kawano
  • Nobuyasu Suganuma
  • Yasushi Rino
  • Munetaka Masuda
  • Kaori Kameyama
  • Hiroshi Takami
  • Koichi Ito
Article

Abstract

Background

Total thyroidectomy is well accepted as initial surgery for papillary thyroid cancer (PTC), but the extent of the thyroidectomy remains a matter of controversy. This study was designed to investigate the long-term clinical outcome of PTC patients who had undergone thyroid lobectomy and to elucidate the indications of lobectomy as initial surgery.

Methods

The cases of 1,088 PTC patients who underwent thyroid lobectomy with curative intent at Ito Hospital between 1986 and 1995 were analyzed retrospectively in this study. None of the patients had received postoperative radioactive iodine (RAI) ablation therapy. The median follow-up period was 17.6 years. All clinical outcomes, including recurrence and death as a result of PTC or other reasons, were evaluated. To establish the indications for lobectomy as initial surgery for PTC, the potential risk factors, such as age, sex, primary tumor size, extrathyroidal invasion, and clinical lymph node metastasis at the time of the initial surgery, were assessed statistically for associations with recurrence and disease-related death.

Results

The remnant-thyroid recurrence-free survival (RT-RFS) rate, the regional- lymph-node recurrence-free survival (L-RFS) rate, and the distant-recurrence-free survival (D-RFS) rate as of 25 years after surgery were 93.5, 90.6, and 93.6%, respectively. The cause-specific survival (CSS) rate at 25 years was 95.2%. Univariate and multivariate analyses showed that none of the factors assessed were significantly associated with the RT-RFS rate. Tumor size, clinical lymph node metastasis, and extrathyroidal invasion were significantly associated with the L-RFS rate. The D-RFS and CSS rates were both significantly lower in the group of patients who were aged 45 years old or older, the group whose tumors were larger than 40 mm, and the group with extrathyroidal invasion. Based on the above findings, we classified the patients into four groups according to age <45 or ≥45 years, tumor size ≤40 or >40 mm, whether clinical lymph node metastasis was present, and whether extrathyroidal invasion was present. None of the patients without any of these four risk factors died of PTC. On the other hand, 22 patients who died of PTC were positive for one or more of these four factors.

Conclusions

The long-term clinical outcome of the PTC patients who had been treated by lobectomy without RAI ablation was excellent. Based on the above results, we concluded that lobectomy is a valid alternative to total thyroidectomy for the treatment of PTC patients who are younger than aged 45 years, whose tumor diameter is 40 mm or less, and who do not have clinical lymph node metastasis or extrathyroidal invasion.

Keywords

Total Thyroidectomy Papillary Thyroid Cancer Distant Recurrence Contralateral Lobe Extrathyroidal Invasion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors acknowledge the contribution that Dr. Kunihiko Ito, who passed away in November 2012, made to the present study. Dr. Ito had been the attending physician of most of the patients included in the study and had participated in the planning and execution of this study.

Conflict of interest

The authors have no conflict of interests to declare.

References

  1. 1.
    American Cancer Society (2011) Cancer Facts & Figures 2011. Available via www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf. Accessed 8 Feb 2012
  2. 2.
    Takami H, Ito Y, Okamoto T et al (2011) Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese society of thyroid surgeons and Japanese association of endocrine surgeons. World J Surg 35:111–121. doi: 10.1007/s00268-010-0832-6 PubMedCrossRefGoogle Scholar
  3. 3.
    Hundahl SA, Fleming ID, Fremgen AM et al (1998) A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 83:2638–2648PubMedCrossRefGoogle Scholar
  4. 4.
    Shigematsu N, Takami H, Ito N et al (2005) Nation survey on the treatment policy for well-differentiated thyroid cancer. Results of a questionnaire distributed at the 37th meeting of the Japanese Society of Thyroid Surgery. Endocr J 52:479–491PubMedCrossRefGoogle Scholar
  5. 5.
    Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1213PubMedCrossRefGoogle Scholar
  6. 6.
    National Comprehensive Cancer Network (2010) NCCN clinical practice guidelines in oncology. Thyroid carcinoma, vol 1. Available via http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed 1 Jan 2013
  7. 7.
    Cobin RH, Gharib H, Bergman DA, Thyroid Carcinoma Task Force et al (2001) AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American college of endocrinology. Endocr Pract 7:202–220PubMedCrossRefGoogle Scholar
  8. 8.
    British Thyroid Association (2007) Guidelines for the management of thyroid cancer, 2nd edn. Available via www.british-thyroid-assiciation.org/news/Docs/Thyroid_cancer_guidelines_2007.pdf. Accessed 8 Feb 2012
  9. 9.
    DeLellis RA, Lloyd RV, Heitz PU et al (2004) WHO classification of tumours, pathology and genetics of tumours of endocrine organs. IRAC Press, Lyon, pp 73–76Google Scholar
  10. 10.
    Hay ID, Bergstralh EJ, Goellner JR et al (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1,779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1058PubMedGoogle Scholar
  11. 11.
    Hay ID, Grant CS, Taylor WF et al (1987) Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088–1094PubMedGoogle Scholar
  12. 12.
    Cady B, Rossi R (1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104:947–953PubMedGoogle Scholar
  13. 13.
    Shaha JP, Loree TR, Dharker D et al (1992) Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 164:658–661CrossRefGoogle Scholar
  14. 14.
    Simpson WJ, McKinney SE, Carruthers JS et al (1987) Papillary and follicular thyroid cancer: prognostic factors in 1,578 patients. Am J Med 83:479–488PubMedCrossRefGoogle Scholar
  15. 15.
    Kingma G, van den Bergen HA, de Vries JE (1991) Prognostic scoring systems in differentiated thyroid carcinoma: which is the best? Neth J Surg 43:63–66PubMedGoogle Scholar
  16. 16.
    Peto R, Pike MC, Armitage P et al (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patients. II. Analysis and examples. Br J Cancer 35:1–39PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Cox DR (1972) Regression models and life tables. J Roy Stat B 34:187–204Google Scholar
  18. 18.
    Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214PubMedCrossRefGoogle Scholar
  19. 19.
    Gharib H, Papini E, Valcavi R, AACE/AME Task Force on Thyroid Nodules et al (2006) American association of clinical endocrinologists and associazione medici endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 12:63–102PubMedGoogle Scholar
  20. 20.
    Pacini F, Schlumberger M, Dralle H, European Thyroid Cancer Taskforce et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803PubMedCrossRefGoogle Scholar
  21. 21.
    Sherman SI, Angelos P, Ball DW, National Comprehensive Cancer Network Thyroid Carcinoma Panel et al (2007) Thyroid Carcinoma. J Natl Compr Canc Netw 5:568–621PubMedGoogle Scholar
  22. 22.
    Bilimoria KY, Bentrem DJ, Ko CY et al (2007) Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246:375–381 discussion 381–384PubMedCrossRefGoogle Scholar
  23. 23.
    Wanebo H, Coburn M, Teates D et al (1998) Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann Surg 227:912–921PubMedCrossRefGoogle Scholar
  24. 24.
    Haigh PI, Urbach DR, Rotstein LE et al (2005) Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol 12:81–89PubMedCrossRefGoogle Scholar
  25. 25.
    Mazzaferri EL, Young RL, Oertel JE et al (1977) Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 56:171–196Google Scholar
  26. 26.
    Russel WO, Ibanz ML, Clark RL et al (1963) Thyroid carcinoma: classification, intraglandular dissemination and clinicopathological study based upon whole organ sections of 80 glands. Cancer 16:1425–1460CrossRefGoogle Scholar
  27. 27.
    Clark RL, White EC, Russel WO (1959) Total thyroidectomy for cancer of the thyroid: significance of intraglandular dissemination. Ann Surg 149:858–866PubMedCrossRefGoogle Scholar
  28. 28.
    Black BM, Kirk TA, Woolner LB (1960) Multicentricity of papillary adenocarcinoma of the thyroid: influence on treatment. J Clin Endocrinol Metab 20:130–135PubMedCrossRefGoogle Scholar
  29. 29.
    Samaan NA, Maheshwari YK, Nader S et al (1983) Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 56:1131–1138PubMedCrossRefGoogle Scholar
  30. 30.
    Grant CS, Hay ID, Gough IR et al (1988) Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery 104:954–962PubMedGoogle Scholar
  31. 31.
    Tollefsen H, Shaha J, Huvos A (1972) Papillary carcinoma of the thyroid. Am J Surg 124:468–472PubMedCrossRefGoogle Scholar
  32. 32.
    Cohn KH, Bäckdahl M, Forsslund G et al (1984) Biologic considerations and operative strategy in papillary thyroid carcinoma: arguments against the routine performance of total thyroidectomy. Surgery 96:957–971PubMedGoogle Scholar
  33. 33.
    Rose RG, Kelsy MP, Russel WO et al (1963) Follow-up study of thyroid cancer treated by unilateral lobectomy. Am J Surg 106:494–500PubMedCrossRefGoogle Scholar
  34. 34.
    Vickery AL, Wang CA, Walker AM (1987) Treatment of intrathyroidal papillary carcinoma of the thyroid. Cancer 60:2587–2595PubMedCrossRefGoogle Scholar
  35. 35.
    Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428PubMedCrossRefGoogle Scholar
  36. 36.
    Mazzaferri EL (1999) An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9:421–427PubMedCrossRefGoogle Scholar
  37. 37.
    Schvartz C, Bonnetain F, Dabakuyo S et al (2012) Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 97:1526–1535PubMedCrossRefGoogle Scholar
  38. 38.
    Gepalakrishna N, Morris LGT, Tuttle RM et al (2011) Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117:4439–4446CrossRefGoogle Scholar
  39. 39.
    Ito Y, Ichihara K, Masuoka H et al (2010) Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J Surg 34:2570–2580. doi: 10.1007/s00268-010-0710-2 PubMedCrossRefGoogle Scholar
  40. 40.
    Sugitani I, Kasai N, Fujimoto Y et al (2004) A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135:139–148PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2013

Authors and Affiliations

  • Kenichi Matsuzu
    • 1
  • Kiminori Sugino
    • 1
  • Katsuhiko Masudo
    • 2
  • Mitsuji Nagahama
    • 1
  • Wataru Kitagawa
    • 1
  • Hiroshi Shibuya
    • 1
  • Keiko Ohkuwa
    • 1
  • Takashi Uruno
    • 1
  • Akifumi Suzuki
    • 1
  • Syunsuke Magoshi
    • 1
  • Junko Akaishi
    • 1
  • Chie Masaki
    • 1
  • Michikazu Kawano
    • 1
  • Nobuyasu Suganuma
    • 2
  • Yasushi Rino
    • 2
  • Munetaka Masuda
    • 2
  • Kaori Kameyama
    • 3
  • Hiroshi Takami
    • 1
  • Koichi Ito
    • 1
  1. 1.Department of SurgeryIto HospitalTokyoJapan
  2. 2.Department of SurgeryYokohama City University HospitalYokohamaJapan
  3. 3.Division of Diagnostic PathologyKeio University HospitalTokyoJapan

Personalised recommendations